697 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Bought by Fielder Capital Group LLC

Key Points

• Fielder Capital Group LLC purchased 697 shares of Medpace Holdings, Inc. for approximately $212,000 in the 1st quarter, amid a trend of increasing institutional investment in the company.
• Wall Street analysts have mixed ratings for Medpace, with a consensus rating of "Hold" and a target price around $411.10, highlighting some analysts' upgraded price targets but also sell ratings.
• Medpace reported a quarterly EPS of $3.10, exceeding estimates, with a revenue of $603.31 million, reflecting a year-over-year growth of 14.2%.

Fielder Capital Group LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 697 shares of the company's stock, valued at approximately $212,000.

A number of other institutional investors also recently bought and sold shares of the business. Summit Creek Advisors LLC increased its stake in Medpace by 9.3% in the first quarter. Summit Creek Advisors LLC now owns 52,232 shares of the company's stock valued at $15,915,000 after purchasing an additional 4,424 shares during the period. Schulhoff & Co. Inc. increased its stake in Medpace by 1.9% in the first quarter. Schulhoff & Co. Inc. now owns 2,680 shares of the company's stock valued at $817,000 after purchasing an additional 50 shares during the period. Bryce Point Capital LLC acquired a new position in Medpace in the first quarter valued at $1,010,000. Nemes Rush Group LLC increased its stake in Medpace by 123.9% in the first quarter. Nemes Rush Group LLC now owns 580 shares of the company's stock valued at $177,000 after purchasing an additional 321 shares during the period. Finally, LPL Financial LLC increased its stake in Medpace by 2.3% in the first quarter. LPL Financial LLC now owns 18,374 shares of the company's stock valued at $5,469,000 after purchasing an additional 414 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

MEDP has been the subject of several recent research reports. Robert W. Baird increased their price target on Medpace from $313.00 to $490.00 and gave the stock a "neutral" rating in a report on Wednesday, July 23rd. Barclays increased their price target on Medpace from $300.00 to $450.00 and gave the stock an "equal weight" rating in a report on Wednesday, July 23rd. TD Cowen reaffirmed a "sell" rating and set a $366.00 price target (up from $283.00) on shares of Medpace in a report on Wednesday, July 23rd. Truist Financial boosted their price target on shares of Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Finally, Cowen lowered shares of Medpace from a "buy" rating to a "sell" rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $411.10.

Medpace Stock Performance

NASDAQ:MEDP opened at $447.49 on Monday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $501.30. The stock has a market capitalization of $12.57 billion, a price-to-earnings ratio of 33.27, a PEG ratio of 2.82 and a beta of 1.47. The stock has a fifty day moving average price of $319.66 and a two-hundred day moving average price of $320.58.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same period last year, the firm earned $2.75 EPS. The company's revenue for the quarter was up 14.2% on a year-over-year basis. On average, analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.